Raise closed, search for fresh raises on Seedstage

Orange, CA

Developing a novel therapeutic to treat Long COVID and improve patient outcomes.

• Mission: Addressing the global health crisis of Long COVID by developing a novel immunotherapy treatment to improve patient outcomes.  
• Innovation: Leverages cancer immunotherapy principles to enhance the immune system’s ability to combat Long COVID and reduce chronic inflammation.  
• Funding Uses: Progressing CVAX-001 into human clinical trials and advancing research and development to create an effective treatment for Long COVID.  
• Healthcare Impact: Aims to alleviate debilitating symptoms of Long COVID and improve the quality of life for millions worldwide.  
• Leadership: Led by a team of experts in healthcare and immunotherapy, dedicated to offering innovative solutions for Long COVID.  
• Strategic Positioning: Focuses on tackling a significant global health challenge with a targeted approach to treating the root causes of Long COVID.  

Coronavax is addressing the pressing global health crisis of Long COVID, which affects millions of individuals and has few effective treatment options currently available. The company is developing a novel therapeutic, CVAX-001, which leverages concepts from cancer immunotherapy to enhance the immune system’s ability to combat infected cells and reduce chronic inflammation.

By administering CVAX-001 via nasal spray, it aims to directly target the virus in the body and stimulate a robust immune response. The fundraising effort is designed to support the progression of CVAX-001 into human clinical trials, ultimately striving to provide a new, effective treatment option for those suffering from Long COVID.

The company seeks to alleviate the debilitating symptoms associated with this condition and improve the quality of life for millions worldwide. With a focus on rigorous research and development, Coronavax aims to bring this innovative solution to market, benefiting both patients and investors alike.

Company Info

Coronavax develops immunotherapy treatments for Long COVID, focusing on reprogramming the immune response to eliminate the virus.

Coronavax is a biotechnology company focused on developing immunotherapy treatments for Long COVID, a condition where COVID-19 symptoms persist long after the initial infection has cleared. The company applies principles of Immuno-Oncology to target and eliminate the virus, aiming to provide patients with a pain-free life. Long COVID affects a significant portion of the population, with estimates suggesting that around 100 million people globally experience symptoms that can severely impact their daily lives. Coronavax has developed a therapeutic called CVAX-001, which is designed to reprogram the immune response to combat Long COVID effectively. The company is led by a team of experts with extensive backgrounds in healthcare and immunotherapy, and they are dedicated to bringing innovative solutions to the challenges posed by Long COVID. Coronavax is also seeking investors to help fund their mission and further their research and development efforts in this area.